Stephan Goldenbaum has worked in biotech since 2003. Until 2017, he was head of sales in Europe, Africa and the Middle East working for QIAGEN, a leading global biotech company. From 2018 until joining Solis BioDyne, Goldenbaum worked on developing sales channels in the large Germany-based biotech company Eppendorf Group. Goldenbaum holds Master’s degrees in biology and business integration.
According to Stephan Goldenbaum, he considers his task to be the improvement of Solis BioDyne’s product development and sales, growing the company’s export volumes and expanding its network of partnerships. “We operate in the market of reagents, where export volumes are measured in millilitres. This means even more work needs to be done in research and development, that drives export. We want to work even more closely with research institutions, primarily the University of Tartu with whom we already have close relations. Solis BioDyne wants to continue to be one of the most attractive employers in Estonia for students and scientists of life-sciences. For example, we are very interested in recruiting people trained in biotechnology, chemistry, gene technology and bioanalytics,” says Goldenbaum.
Solis BioDyne is also preparing to build a larger and more modern new office and production building on Palsa Street in Tartu. “We are starting to outgrow our current premises in Tartu Science Park because our staff and production volumes have multiplied over the past couple of years. We hope to move into the new building equipped with a state-of-the-art biotech research and development unit in a year’s time,” explains Goldenbaum.
Salim Essakali, who also has long-term experience from the biotechnology company QIAGEN and the manufacturer of medical devices Boston Scientific, will also start working as the Head of Global Sales and Marketing of Solis BioDyne on September 1. 2021.
He has conducted his Master of Science in Molecular Pathology, holds an MBA in Corporate Strategy, and has extensive management experience developing, commercializing, and life-cycle-managing in BioTech and MedTech field.
OÜ Solis BioDyne operating in Tartu Science Park is one of Estonia’s leading biotech companies developing and producing reagents. DNA polymerases, PCR Master Mixes, qPCR Mixes and reverse transcription reagents are highly valued across the globe. Majority of its exports end up in Europe and the United States of America. Solis BioDyne uses unique genetic modification within all products to make them stable at room temperature for 30 days, to provide more sustainable and cost-effective solutions. The company was established in 1995 and now employs over 60 people.
Further information:
Sigrid HänniMarketing and Communication ManagerSOLIS BIODYNE OÜA: Teaduspargi 9, 50411 Tartu, EstoniaT: +372 5682 5751E: sigrid.hanni@solisbiodyne.comW: www.solisbiodyne.com
Ribonucleases or RNases are native proteins that can degrade RNA molecules. To mitigate risks we rely on RNase inhibitors, which are invaluable tools to protect and preserve RNA molecules in diverse biotechnological applications.
There are two options for target detection when doing qPCR - either you use dye or probe-based detection. Today we are going to take a deep dive into the world of dye-based qPCR, which was invented during the early nineties by Russell Higuchi [1] and is still used daily around the world.
Depression is a very complex disease, and it has many different aspects that affect it. Once we get to know more and more things about depression and its mechanisms, then in the end, we might discover new possible drugs or drug targets for treating depression.
If you ever need someone to help you with your computer, fix your house, join you in a sports competition, or just be a friend, Marek is your guy. Being one of the friendliest, most helpful people out there certainly makes him a really cool person everyone should know more about.
